Terms: = Lymphoma AND EZH2, ENX-1, 2146, ENSG00000106462, Q15910, MGC9169 AND Treatment
178 results:
1. Thyroid papillary carcinoma combined with primary follicular lymphoma: a case report.
Xu T; Wu L; Ye H; Luo S; Wang J
Diagn Pathol; 2024 May; 19(1):69. PubMed ID: 38773600
[TBL] [Abstract] [Full Text] [Related]
2. Discovery of novel pyridone-benzamide derivatives possessing a 1-methyl-2-benzimidazolinone moiety as potent ezh2 inhibitors for the treatment of B-cell lymphomas.
Wu D; Zeng X; Zhao Y; Qin M; Gong P
Bioorg Med Chem; 2024 May; 105():117725. PubMed ID: 38640588
[TBL] [Abstract] [Full Text] [Related]
3. Pharmacology and pharmacokinetics of tazemetostat.
Orleni M; Beumer JH
Cancer Chemother Pharmacol; 2024 May; 93(5):509-517. PubMed ID: 38520556
[TBL] [Abstract] [Full Text] [Related]
4. Mechanisms of action and resistance in histone methylation-targeted therapy.
Yamagishi M; Kuze Y; Kobayashi S; Nakashima M; Morishima S; Kawamata T; Makiyama J; Suzuki K; Seki M; Abe K; Imamura K; Watanabe E; Tsuchiya K; Yasumatsu I; Takayama G; Hizukuri Y; Ito K; Taira Y; Nannya Y; Tojo A; Watanabe T; Tsutsumi S; Suzuki Y; Uchimaru K
Nature; 2024 Mar; 627(8002):221-228. PubMed ID: 38383791
[TBL] [Abstract] [Full Text] [Related]
5. A miniaturized mode-of-action profiling platform enables high throughput characterization of the molecular and cellular dynamics of ezh2 inhibition.
Falkenstern L; Georgi V; Bunse S; Badock V; Husemann M; Roehn U; Stellfeld T; Fitzgerald M; Ferrara S; Stöckigt D; Stresemann C; Hartung IV; Fernández-Montalván A
Sci Rep; 2024 Jan; 14(1):1739. PubMed ID: 38242973
[TBL] [Abstract] [Full Text] [Related]
6. Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell lymphoma: Data from the First-in-Human Phase I Study.
Song Y; Jin Z; Li ZM; Liu Y; Li L; He C; Su H; Zhou H; Li K; Hao S; Zuo X; Wu J; Li D; Wu M; Sun X; Qi J; Cai Z; Li Z; Li Y; Huang Y; Shen J; Xiao Z; Zhu J
Clin Cancer Res; 2024 Apr; 30(7):1248-1255. PubMed ID: 38190117
[TBL] [Abstract] [Full Text] [Related]
7.
Choi YJ; Min YK; Lee ST; Choi JR; Shin S
Ann Lab Med; 2024 Jul; 44(4):335-342. PubMed ID: 38145892
[TBL] [Abstract] [Full Text] [Related]
8. Recurrent Mutations in Refractory/Relapsed Diffuse Large B-Cell lymphoma by Targeted Gene Sequencing.
Sharma A; Das A; Bal A; Srinivasan R; Malhotra P; Prakash G; Kumar R
Cytogenet Genome Res; 2023; 163(5-6):279-289. PubMed ID: 38071955
[TBL] [Abstract] [Full Text] [Related]
9. ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms.
Arribas AJ; Napoli S; Cascione L; Barnabei L; Sartori G; Cannas E; Gaudio E; Tarantelli C; Mensah AA; Spriano F; Zucchetto A; Rossi FM; Rinaldi A; Castro de Moura M; Jovic S; Bordone Pittau R; Stathis A; Stussi G; Gattei V; Brown JR; Esteller M; Zucca E; Rossi D; Bertoni F
Mol Cancer Ther; 2024 Mar; 23(3):368-380. PubMed ID: 38052765
[TBL] [Abstract] [Full Text] [Related]
10. ezh2 K63-polyubiquitination affecting migration in extranodal natural killer/T-cell lymphoma.
Li B; Zhou Q; Wan Q; Qiao X; Chen S; Zhou J; Wuxiao Z; Luo L; Ng SB; Li J; Chng WJ
Clin Epigenetics; 2023 Nov; 15(1):187. PubMed ID: 38031139
[TBL] [Abstract] [Full Text] [Related]
11. Establishment of ganglioside GD2-expressing extranodal NK/T-cell lymphoma cell line with scRNA-seq analysis.
Sato S; Ishii M; Tachibana K; Furukawa Y; Toyota T; Kinoshita S; Azusawa Y; Ando J; Ando M
Exp Hematol; 2024 Feb; 130():104132. PubMed ID: 38029851
[TBL] [Abstract] [Full Text] [Related]
12. Long non-coding RNA SNHG17 may function as a competitive endogenous RNA in diffuse large B-cell lymphoma progression by sponging miR-34a-5p.
Lu S; Zeng L; Mo G; Lei D; Li Y; Ou G; Wu H; Sun J; Rong C; He S; Zhong D; Ke Q; Zhang Q; Tan X; Cen H; Xie X; Liao C
PLoS One; 2023; 18(11):e0294729. PubMed ID: 37988356
[TBL] [Abstract] [Full Text] [Related]
13. Conformationally constrained potent inhibitors for enhancer of zeste homolog 2 (ezh2).
Xu X; Chen J; Wang G; Zhang X; Li Q; Zhou X; Guo F; Li M
Bioorg Med Chem Lett; 2024 Jan; 97():129558. PubMed ID: 37956762
[TBL] [Abstract] [Full Text] [Related]
14. Synchronous T-lymphoblastic lymphoma and neuroblastoma in a 3-yr-old with novel germline
Tibout P; Livingston J; Kanwar N; Yuki KE; Shlien A; Ngan B; Irwin MS; Morgenstern DA; Hitzler J; Villani A; Cohen-Gogo S
Cold Spring Harb Mol Case Stud; 2023 Dec; 9(4):. PubMed ID: 37932047
[TBL] [Abstract] [Full Text] [Related]
15. TP63 fusions drive multicomplex enhancer rewiring, lymphomagenesis, and ezh2 dependence.
Wu G; Yoshida N; Liu J; Zhang X; Xiong Y; Heavican-Foral TB; Mandato E; Liu H; Nelson GM; Yang L; Chen R; Donovan KA; Jones MK; Roshal M; Zhang Y; Xu R; Nirmal AJ; Jain S; Leahy C; Jones KL; Stevenson KE; Galasso N; Ganesan N; Chang T; Wu WC; Louissaint A; Debaize L; Yoon H; Dal Cin P; Chan WC; Ho Sui SJ; Ng SY; Feldman AL; Horwitz SM; Adelman K; Fischer ES; Chen CW; Weinstock DM; Brown M
Sci Transl Med; 2023 Sep; 15(714):eadi7244. PubMed ID: 37729434
[TBL] [Abstract] [Full Text] [Related]
16. Exploiting the fibroblast growth factor receptor-1 vulnerability to therapeutically restrict the MYC-ezh2-CDKN1C axis-driven proliferation in Mantle cell lymphoma.
Sircar A; Singh S; Xu-Monette ZY; Coyle KM; Hilton LK; Chavdoula E; Ranganathan P; Jain N; Hanel W; Tsichlis P; Alinari L; Peterson BR; Tao J; Muthusamy N; Baiocchi R; Epperla N; Young KH; Morin R; Sehgal L
Leukemia; 2023 Oct; 37(10):2094-2106. PubMed ID: 37598282
[TBL] [Abstract] [Full Text] [Related]
17. Safety, Tolerability, and Pharmacokinetics of Valemetostat Tablets and the Effect of Food on Valemetostat Pharmacokinetics in Healthy Subjects: Two Phase 1 Studies.
Tachibana M; Matsuki S; Toyama K; Maekawa Y; Fukae M; Shimizu T; Tsutsumi J; Shinohara S; Ishizuka H
Clin Pharmacol Drug Dev; 2024 Jan; 13(1):77-86. PubMed ID: 37565616
[TBL] [Abstract] [Full Text] [Related]
18. [EZH inhibitors in lymphoma therapy].
Ishitsuka K
Rinsho Ketsueki; 2023; 64(7):665-669. PubMed ID: 37544728
[TBL] [Abstract] [Full Text] [Related]
19. Integrative Multi-Omics Analysis of Oncogenic ezh2 Mutants: From Epigenetic Reprogramming to Molecular Signatures.
Aldana J; Gardner ML; Freitas MA
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511137
[TBL] [Abstract] [Full Text] [Related]
20. Parallel testing of liquid biopsy (ctDNA) and tissue biopsy samples reveals a higher frequency of ezh2 mutations in follicular lymphoma.
Nagy Á; Bátai B; Kiss L; Gróf S; Király PA; Jóna Á; Demeter J; Sánta H; Bátai Á; Pettendi P; Szendrei T; Plander M; Körösmezey G; Alizadeh H; Kajtár B; Méhes G; Krenács L; Timár B; Csomor J; Tóth E; Schneider T; Mikala G; Matolcsy A; Alpár D; Masszi A; Bödör C
J Intern Med; 2023 Sep; 294(3):295-313. PubMed ID: 37259686
[TBL] [Abstract] [Full Text] [Related]
[Next]
